Trial reportFertility and sterility2012
Impact of cancer therapies on ovarian reserve.
Trial report in Fertility and sterility, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01143844 (Assessing Fertility Potential in Female Cancer Survivors), which is not on this map. Cited by 92 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing Fertility Potential in Female Cancer Survivors
Who cites it
92 citing papers in PubMed, 5 syntheses or guidelines pooled it, 216 citations in OpenAlex.
- Fertility status in childhood cancer survivors of hematological malignancies: a systematic review.Hormones (Athens, Greece) · 2023Pooled it
- Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.Human reproduction update · 2022Pooled it
- Risk factors for inadequate response to ovarian stimulation in assisted reproduction cycles: systematic review.Journal of assisted reproduction and genetics · 2019Pooled it
- Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Guideline
- Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review.Reproductive biology and endocrinology : RB&E · 2014Pooled it
- The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.European journal of cancer (Oxford, England : 1990) · 2017Trial
- Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy.Fertility and sterility · 2013Trial
- Longitudinal Ovarian Reserve in Female Adolescents/Young Adults With Lymphoma: A Report From Children's Oncology Group Study ALTE11C1.Pediatric blood & cancer · 2026Article
- Fertility Preservation in Female Patients with Cancer. Part III: Royan Human Ovarian Tissue Bank Guideline for Prepubertal Girls and Women, A Review.International journal of fertility & sterility · 2026Article
- [Fertility management in breast cancer patients: current strategies and research advances].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Uncontrolled diabetes may cause a transient decrease in ovarian reserve parameters to a suboptimal level: Recovery with optimized glycemic control - A case report.JBRA assisted reproduction · 2025Article
- Single euploid embryo transfer outcomes following cancer and systemic chemotherapy.Journal of assisted reproduction and genetics · 2025Article
- Fertility preservation and mental health among cancer patients of reproductive age.Fertility and sterility · 2025Review
- The Final Phases of Ovarian Aging: A Tale of Diverging Functional Trajectories.Journal of clinical medicine · 2025Review
- Diminished Ovarian Reserve: A Narrative Review of Etiologies and Possible Therapeutic Approaches.Journal of menopausal medicine · 2025Review
- Granulosa cell death is a significant contributor to DNA-damaging chemotherapy-induced ovarian insufficiency†.Biology of reproduction · 2025Article
- Molecular Factors Predicting Ovarian Chemotoxicity in Fertile Women: A Systematic Review.Cancers · 2024Review
- Review
- The use of fertility treatments among reproductive-aged women after cancer.Fertility and sterility · 2024Article
- Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo determine whether measures of ovarian reserve differ between females exposed to cancer therapies in a dose-dependent manner as compared with healthy controls of similar age and late reproductive age.
designCross-sectional analysis of data from a prospective cohort study.
settingUniversity medical center. PATIENT(S): Seventy-one cancer survivors aged 15-39 years; 67 healthy, similarly aged unexposed subjects; and 69 regularly menstruating women of late reproductive age (40-52 years). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Early follicular-phase hormones (FSH, E(2), inhibin B, antimüllerian hormone [AMH]) and ovarian ultrasound measurements (ovarian volume and antral follicle counts [AFC]) were compared using multivariable linear regression. RESULT(S): In adjusted models, FSH, AMH, and AFC differed between exposed vs. unexposed subjects (FSH 11.12 mIU/mL vs. 7.25 mIU/mL; AMH 0.81 ng/mL vs. 2.85 ng/mL; AFC 14.55 vs. 27.20). In participants with an FSH <10 mIU/mL, survivors had lower levels of AMH and AFC compared with controls. Alkylating agent dose score was associated with increased levels of FSH and decreased levels of AMH. Exposure to pelvic radiation was associated with impairment in FSH, AMH, AFC, and ovarian volume. Antimüllerian hormone was similar in women previously exposed to high-dose cancer therapy and 40-42-year-old controls. CONCLUSION(S): Measures of ovarian reserve are impaired in a dose-dependent manner among cancer survivors compared with unexposed females of similar age. Reproductive hormone levels in menstruating survivors exposed to high-dose therapy are similar to those in late-reproductive-age women. The predictive value of measures for pregnancy and menopause must be studied. CLINICALTRIALS.GOV IDENTIFIER: NCT01143844.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.